Cargando…

Mulberry Component Kuwanon C Exerts Potent Therapeutic Efficacy In Vitro against COVID-19 by Blocking the SARS-CoV-2 Spike S1 RBD:ACE2 Receptor Interaction

There has been an immense effort by global pharmaceutical companies to develop anti-COVID-19 drugs, including small molecule-based RNA replication inhibitors via drug repositioning and antibody-based spike protein blockers related to cell entry by SARS-CoV-2. However, several limitations to their cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Young Soo, Kwon, Eun-Bin, Kim, Buyun, Chung, Hwan-Suck, Choi, Garam, Kim, Yeoun-Hee, Choi, Jang-Gi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604257/ https://www.ncbi.nlm.nih.gov/pubmed/36293371 http://dx.doi.org/10.3390/ijms232012516

Ejemplares similares

Investigation of potential inhibitor properties of violacein against HIV-1 RT and CoV-2 Spike RBD:ACE-2
por: Dogancı, Merve Ayse, et al.
Publicado: (2022)

A Suitable Membrane Distance Regulated by the RBD_ACE2 Interaction is Critical for SARS‐CoV‐2 Spike‐Mediated Viral Invasion
por: Wu, Mengdan, et al.
Publicado: (2023)

Geraniin Inhibits the Entry of SARS-CoV-2 by Blocking the Interaction between Spike Protein RBD and Human ACE2 Receptor
por: Kim, Young Soo, et al.
Publicado: (2021)

Mulberrofuran G, a Mulberry Component, Prevents SARS-CoV-2 Infection by Blocking the Interaction between SARS-CoV-2 Spike Protein S1 Receptor-Binding Domain and Human Angiotensin-Converting Enzyme 2 Receptor
por: Kim, Young Soo, et al.
Publicado: (2022)

Differential interactions between human ACE2 and spike RBD of SARS-CoV-2 variants of concern
por: Kim, Seonghan, et al.
Publicado: (2022)

Differential Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern
por: Kim, Seonghan, et al.
Publicado: (2021)

Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction
por: Cao, Wenpeng, et al.
Publicado: (2021)

COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
por: Junker, Daniel, et al.
Publicado: (2022)

Peptide modelling and screening against human ACE2 and spike glycoprotein RBD of SARS-CoV-2
por: Rathod, Shravan B., et al.
Publicado: (2020)

A Collection of Designed Peptides to Target SARS-CoV-2 Spike RBD—ACE2 Interaction
por: Fernandez-Fuentes, Narcis, et al.
Publicado: (2021)

Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
por: Hoter, Abdullah, et al.
Publicado: (2022)

A Mulberry Diels-Alder-Type Adduct, Kuwanon M, Triggers Apoptosis and Paraptosis of Lung Cancer Cells through Inducing Endoplasmic Reticulum Stress
por: Ma, Mengjiao, et al.
Publicado: (2023)

Effect of Delta and Omicron Mutations on the RBD-SD1 Domain of the Spike Protein in SARS-CoV-2 and the Omicron Mutations on RBD-ACE2 Interface Complex
por: Ching, Wai-Yim, et al.
Publicado: (2022)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiangdong, et al.
Publicado: (2020)

Dynamic Assay for Profiling Anti-SARS-CoV-2 Antibodies and Their ACE2/Spike RBD Neutralization Capacity
por: Phelan, Thomas, et al.
Publicado: (2021)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiandong, et al.
Publicado: (2021)

Analyzing the interaction of human ACE2 and RBD of spike protein of SARS-CoV-2 in perspective of Omicron variant
por: Samanta, Arijit, et al.
Publicado: (2022)

Entropic contribution of ACE2 glycans to RBD binding
por: Mugnai, Mauro L., et al.
Publicado: (2023)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
por: Shah, Masaud, et al.
Publicado: (2020)

Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
por: Han, Pengcheng, et al.
Publicado: (2022)

Mutational scanning of spike RBD protein for enhanced ACE2 affinity emerging Southeast Asia in the late transmission phase
por: Kodchakorn, Kanchanok, et al.
Publicado: (2022)

Kuwanon T and Sanggenon A Isolated from Morus alba Exert Anti-Inflammatory Effects by Regulating NF-κB and HO-1/Nrf2 Signaling Pathways in BV2 and RAW264.7 Cells
por: Ko, Wonmin, et al.
Publicado: (2021)

Kuwanon V Inhibits Proliferation, Promotes Cell Survival and Increases Neurogenesis of Neural Stem Cells
por: Kong, Sun-Young, et al.
Publicado: (2015)

Scanning the RBD-ACE2 molecular interactions in Omicron variant
por: Rath, Soumya Lipsa, et al.
Publicado: (2022)

In silico study of intrinsic dynamics of full-length apo-ACE2 and RBD-ACE2 complex
por: Liu, Qing, et al.
Publicado: (2021)

Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2
por: Gurung, Arun Bahadur, et al.
Publicado: (2021)

Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor
por: Gurung, Arun Bahadur, et al.
Publicado: (2022)

Recombinant ACE2 protein protects against acute lung injury induced by SARS-CoV-2 spike RBD protein
por: Zhang, Lingbing, et al.
Publicado: (2022)

DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach
por: Silwal, Achut Prasad, et al.
Publicado: (2022)

The Development of Pharmacophore Models for the Search of New Natural Inhibitors of SARS-CoV-2 Spike RBD–ACE2 Binding Interface
por: Semenov, Valentin A., et al.
Publicado: (2022)

Immunoglobulin yolk targeting spike 1, receptor binding domain of spike glycoprotein and nucleocapsid of SARS-CoV-2 blocking RBD-ACE2 binding interaction
por: Eka Saputri, Meliana, et al.
Publicado: (2022)

A novel rapid detection for SARS-CoV-2 spike 1 antigens using human angiotensin converting enzyme 2 (ACE2)
por: Lee, Jong-Hwan, et al.
Publicado: (2021)

A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2
por: Wang, Xiaoning, et al.
Publicado: (2021)

Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics
por: Barton, Michael I, et al.
Publicado: (2021)

Dual-detection fluorescent immunochromatographic assay for quantitative detection of SARS-CoV-2 spike RBD-ACE2 blocking neutralizing antibody
por: Duan, Xuejun, et al.
Publicado: (2022)

Computational prediction of the effect of amino acid changes on the binding affinity between SARS-CoV-2 spike RBD and human ACE2
por: Chen, Chen, et al.
Publicado: (2021)

A CNN model for predicting binding affinity changes between SARS-CoV-2 spike RBD variants and ACE2 homologues
por: Chen, Chen, et al.
Publicado: (2022)

Thermodynamic analysis of the interactions between human ACE2 and spike RBD of Betacoronaviruses (SARS‐CoV‐1 and SARS‐CoV‐2)
por: Rombel‐Bryzek, Agnieszka, et al.
Publicado: (2022)

Evaluation of Selective COX-2 Inhibition and In Silico Study of Kuwanon Derivatives Isolated from Morus alba
por: Baek, Seung-Hwa, et al.
Publicado: (2021)

Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective
por: Borkotoky, Subhomoi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_04dkgeeiqso4s6hi0fr3leth5d